RxDoctor Payments Data

Bradley Hiner, MD

Neurology · Oxnard, CANPI 1326099151

Payments from drug & device makers

$1,575in general payments, 2019–2025

Across 45 payments — averaging $35.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$866
  • AbbVie$373
  • Amneal Pharmaceuticals LLC$67
  • Medtronic$59
  • Sunovion Pharmaceuticals Inc.$49
  • Biohaven Pharmaceuticals, Inc.$44
  • plus $116 from 5 others

What the payments were for

  • Food & beverage$1,575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,575 in reported general payments places this provider in the 50th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$175,660
Medicare patients
312
Services billed
9,543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine17$115,762
NuplazidPimavanserin Tartrate12$59,940
RytaryCarbidopa/Levodopa55$36,620
Carbidopa-LevodopaCarbidopa/Levodopa548$24,149
Propranolol Hcl ErPropranolol Hcl140$7,267
Entacapone28$3,442
Midodrine Hcl24$3,122
Carbidopa-Levodopa ErCarbidopa/Levodopa42$2,934
AmantadineAmantadine Hcl29$1,866
Primidone67$1,750
Ropinirole ErRopinirole Hcl12$1,663
Donepezil Hcl136$1,609
Rivastigmine11$1,290
Memantine Hcl43$1,212
Ropinirole Hcl43$945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$26$59,94012 claims
Amneal Pharmaceuticals LLCRytary$67$36,62055 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,996 neurology providers in California.

Other neurology in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →